Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus BRONKOMETER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus BRONKOMETER.
AQUAPHYLLIN vs BRONKOMETER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Category C
Category C
Bronchodilator
Bronchodilator